Evidence map›Paper›PMID 36763627›Full record

Trial reportPloS one2023

A UVR-sensor wearable device intervention to reduce sun exposure in melanoma survivors: Results from a randomized controlled trial.

Rachel Isaksson Vogel, Xianghua Luo, Katherine Brown, Patricia Jewett, Allison C Dona, Rebekah H Nagler, Rehana L Ahmed, Brian C Martinson, DeAnn Lazovich

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03927742 (Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03927742 nacompletednot on this map

Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors

TypeinterventionalSponsorUniversity of MinnesotaRan2020 to 2022Enrolled368ConditionsMelanoma (Skin)ArmsShade + app with messaging, Shape + app without messaging
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. [Chronic skin damage from UV radiation].Dermatologie (Heidelberg, Germany) · 2026
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Rachel Isaksson VogelDepartment of Obstetrics, Gynecology and Women's Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, Minnesota, United States of America.ORCID 0000-0003-0149-8464
Xianghua LuoMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States of America.ORCID 0000-0001-7501-6582
Katherine BrownDepartment of Obstetrics, Gynecology and Women's Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, Minnesota, United States of America.
Patricia JewettDepartment of Obstetrics, Gynecology and Women's Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, Minnesota, United States of America.
Allison C DonaMedical School, University of Minnesota, Minneapolis, Minnesota, United States of America.
Rebekah H NaglerMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States of America.
Rehana L AhmedMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States of America.
Brian C MartinsonHealthPartners Institute, Bloomington, Minnesota, United States of America.
DeAnn LazovichMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States of America.
University of Minnesota · USUniversity of Minnesota Medical Center · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
NCATS NIH HHS UL1 TR002494NCI NIH HHS P30 CA077598
6 · The paper itself

Abstract

backgroundMelanoma survivors are at increased risk of developing a second primary melanoma; however, some report sub-optimal sun behaviors and sunburns. We tested the effectiveness of a wearable device with ultraviolet radiation (UVR)-sensing technology to improve sun behaviors and reduce sunburns in cutaneous melanoma survivors. MATERIALS AND

methodsWe conducted a randomized controlled trial using Shade 2, a commercially available wrist device that measures UVR. The intervention group received the device and mobile application notifications about their exposure and prompts to use sunscreen. The control group received the device and a separate research mobile application without information about their exposure or notifications. Participants wore the device for 12 weeks and self-reported sun behaviors before, during, and after the intervention. The primary outcome was a composite score of sun protection behaviors at week 12.

results386 participants were randomized (186 control, 182 intervention). Most were female and 5+ years past their first melanoma diagnosis. The average age was 56 years. Most (93%) completed the study, though 40% experienced device issues. No meaningful differences were observed in self-reported sun protection behaviors at week 12 (controls 3.0±0.5 vs. intervention 2.9±0.5, p = 0.06), any sunburn during the intervention period (controls 14.4% vs. intervention 12.7%, p = 0.75), or average daily objective UVR exposure (controls median 87 vs. intervention 83 J/m2, p = 0.43).

conclusionWearing a device that measured and alerted melanoma survivors to UVR exposure did not result in different sun behaviors, exposure, or sunburns relative to controls. The technology needs refinement before further attempts to assess the effectiveness of self-monitoring UVR exposure. CLINICAL TRIALS REGISTRATION: NCT03927742.

Indexed as

Cancer SurvivorsMelanomaSkin NeoplasmsSunburnFemaleHumansMaleMiddle AgedSunlightSunscreening AgentsUltraviolet RaysSunscreening Agents

Identifiers

PMID36763627
PMCPMC9916644
OpenAlexW4319827384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.